United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Health and Human Services Secretary Alex Azar said Thursday he'd like “more visibility” into Pfizer's Covid vaccine manufacturing, adding Pfizer has kept the federal government at “arm's length.”

HHS Secretary Azar says Pfizer keeps government at 'arm's length' on Covid vaccine manufacturing

The failure to launch really isn't all that surprising.

Why Didn't Pfizer Stock Jump More After Winning Authorization for Its COVID Vaccine?

Extra doses contained in the vials of Pfizer Inc's (NYSE: PFE) COVID-19 vaccine do not need to be discarded, according to the United States Food and Drug Administration, Reuters reported Wednesday.  What Happened: Labeling confusion had led to hospital pharmacists discarding one in every six doses of the vaccine made jointly by Pfizer and its German partner BioNTech SE (NASDAQ: BNTX), Stat News had reported earlier.

Pfizer COVID-19 Vaccine US Supply Could Rise 40% As FDA Clears Use Of Extra Doses In Vials

Hospital pharmacists in the US have been throwing out extra COVID-19 vaccine doses as the country battles with record numbers of infections and deaths.

Pfizer vaccine doses thrown away in US after labelling confusion

But some doses may have already been thrown away.

Report: Pfizer Vaccine Vials Hold Extra Doses—Increasing U.S. Supply By Up To 40%

Delta Air Lines

Delta Air Lines (NYSE: DAL) said it has delivered two shipments of Pfizer Inc.'s COVID-19 vaccine, joining American Airlines (NASDQ: AAL) and United Airlines in supporting distribution of the initial wave of doses to the American public. Delta said it transported the shipments from Detroit to Atlanta and San Francisco on regularly scheduled passenger flights.

Delta Air Lines moves Pfizer vaccine on passenger flights (with video)

Arcosa Inc

Amazon

Salesforce

Masco

Although stocks surged yesterday on stimulus hopes, the indices showed some signs of weakness this morning reflecting the mixed bag of news being thrown at investors on a daily basis. For investors looking to make the most of this market, our AI has crunched the data to give you a set of Top Buys.

Top Stocks To Buy Today As Markets Respond To Mixed Sentiment

Doses of Pfizer's vaccine were quarantined in California and Alabama after an “anomaly” in the transportation process caused the storage temperature to get too cold.

U.S. quarantines Pfizer vaccine shipments in California and Alabama after transit 'anomaly' left vials too cold

Moderna

Moderna and Pfizer have quickly developed highly effective vaccines that should help to end the Covid-19 pandemic. With Pfizer's vaccine already rolling out in the U.K, and the U.S. in limited quantities, and Moderna's likely to follow suit in the coming weeks, investors are likely trying to.

Pfizer And Moderna's Vaccines Could Be More Profitable Than You Think

The Moderna and Pfizer vaccines have one key similarity.

What Pfizer's Vaccine Authorization Means for Moderna

AstraZeneca

Sanofi

The challenges for two big drugmakers could translate to opportunities for their rivals in the COVID-19 vaccine race.

Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

Millions of doses of Pfizer Inc (NYSE: PFE) and BioNTech SE's  (NASDAQ: BNTX) COVID-19 vaccine will be administered in China alongside home-made options, Bloomberg reported Tuesday. What Happened: Local pharmaceutical firm Shanghai Fosun Pharmaceutical (Group) Co, Ltd (OTC: SFOSF) —  which signed an agreement with BioNTech in March — will pay the German company $300 million (EUR 250 million) for an initial 50 million doses, according to Bloomberg.

China Secures 100M Doses Of Pfizer-BioNTech COVID-19 Vaccine For 2021

Airbnb

Etsy

First Republic

Palantir Technologies

PayPal

Teladoc

Verisk Analytics

These best long-term stocks can help boost any diversified portfolio. Here are eight picks with particularly strong potential for the years to come.

The 8 Best Long-Term Stocks with Plenty of Potential

Sellers are striking Pfizer stock , even as it rolls out its novel coronavirus vaccine. Ignore the weakness, and buy with short puts.

Here's How To Bull Trade The Dip In Pfizer Stock With Finesse

The FDA said that there were four reported cases of Bell's palsy among Moderna's 30,000 trial participants, including three who got the vaccine.

FDA staff recommends watching for Bell's palsy in Moderna and Pfizer vaccine recipients

FedEx

Trane Technologies plc

Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -

5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins

A World Health Organization senior official said on Tuesday that the agency was in talks with Pfizer to include its COVID-19 vaccine as part of an early global roll out.

WHO sees "strong commitment" from Pfizer on affordable COVID vaccine

Which Is the Best COVID Vaccine Stock Now: Pfizer, BioNTech, or Moderna?

Blackrock Inc

GrubHub

Lululemon Athletica

Microsoft

Peloton

This year's holiday season is anything but typical due to Covid-19. Here are seven Christmas stocks to buy that are atypical from past years.

7 Christmas Stocks to Buy for 2020's Atypical Holidays

Although December has largely kept November's election and vaccine rally moving, markets fell for the first week in three last week. Among all the news and data spurring on the markets, our deep learning algorithms have used AI technology to rate the Top Trending Stocks for this week.

Pfizer Rated Top Buy This Week As Vaccine Distribution Kicks Off

Abbott Labs

Bristol-Myers

Dividend increase announcements continue to pile up as 2020 draws to a close. The health care sector remains one of my favorite places to find stocks offering solid yields and lengthy track records of dividend growth.

3 Health Care Companies That Recently Raised Dividends

"There is not one part of this country that's not being touched today through Wednesday," Gen. Gustave Perna, who's in charge of logistics for Operation Warp Speed, said.

U.S. administers first shots of Pfizer's Covid vaccine, launching a historic rollout

iShares MSCI Emerging Markets ETF

SPDR S&P 500 ESG ETF

iShares iBoxx High Yield Corporate Bond ETF

iShares Core MSCI Emerging Markets ETF

SPDR S&P 500 ETF Trust

iShares 20+ Year Treasury Bond ETF

Energy Select Sector SPDR Fund

2020 has already featured a number of short-term leadership shifts. I expect that trend to continue in 2021.

5 Potential Thematic Rotations That I Expect To Take Place In 2021

News for Pfizer Stock (PFE)